Chen, D <br/><br/>
Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.  [electronic resource] 

 -  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology  Sep 2013 
 - 974-80 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-2157 
<br/><br/><label>Standard No.: </label>10.1016/j.ejso.2013.06.018  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Hepatocellular--drug therapy<br/>Extracellular Signal-Regulated MAP Kinases--metabolism<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Liver Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Niacinamide--analogs & derivatives<br/>PTEN Phosphohydrolase--metabolism<br/>Phenylurea Compounds--therapeutic use<br/>Phosphorylation<br/>Prognosis<br/>Ribosomal Protein S6 Kinases, 70-kDa--metabolism<br/>Sorafenib<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor Receptor-2--metabolism<br/>Young Adult